Physician profile
Lyna K Lee
NPI 1538165618
$7,408.63
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $1,256 · 2021: $1,519 · 2022: $2,267 · 2023: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,119.58 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,090.21 | 2019-2023 | Fasenra, Tezspire, Breztri |
| Novartis Pharmaceuticals Corporation | $645.05 | 2019-2023 | |
| Kaleo, INC. | $489.89 | 2019-2023 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $466.30 | 2019-2023 | Dupixent |
| Csl Behring | $460.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $396.26 | 2020-2023 | Cuvitru, Takhzyro, Hyqvia |
| Teva Pharmaceuticals USA, INC. | $352.97 | 2021-2023 | Airduo Digihaler |
| Abbvie INC. | $336.39 | 2022-2023 | |
| Optinose US, INC. | $333.20 | 2019-2023 | |
| Genzyme Corporation | $262.25 | 2019-2023 | |
| Pfizer INC. | $253.98 | 2019-2023 | |
| Grifols USA, LLC | $225.32 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $196.71 | 2021-2023 | Orladeyo |
| Octapharma USA, INC. | $144.51 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.81 | 2021-2023 | Tezspire |
| Incyte Corporation | $101.49 | 2021-2023 | Opzelura |
| Shire North American Group INC | $98.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.15 | 2021-2022 | |
| Alk-Abello, INC | $50.15 | 2019-2022 | |
| Mylan Specialty L.P. | $48.27 | 2020 | |
| Leo Pharma INC. | $40.70 | 2022-2023 | Adbry |
| Blueprint Medicines Corporation | $27.74 | 2023 | Ayvakit |
| Sanofi Pasteur INC. | $18.09 | 2023 | |
| Pharming Healthcare, INC. | $17.28 | 2023 | Ruconest |
| Circassia INC. | $12.74 | 2019 | |
| Hikma Pharmaceuticals USA | $12.07 | 2022 | |
| Celgene Corporation | $11.50 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyna Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.